Skip to contentA
Aclaris Therapeutics, Inc.
A
ACRSAclaris Therapeutics, Inc. Q4 2017 · 10-K
Revenue$999.00K$999.00Kno prior Q4 2016 on file Net Income-$22.93M-$22.93MN/M vs Q4 2016 EPS Diluted-$0.74-$0.74N/M vs Q4 2016 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aclaris Therapeutics, Inc. · CIK 1557746 · Engraved from SEC EDGAR
derived
Operating Cash Flowderived-$18,210,000N/M Free Cash Flowderived-$18,787,000N/M Margins · derivedGross margin24.5%
Operating margin-738.7%
Net margin-2295.7%
ended Dec 31, 2017 · filed Mar 12, 2018 · 71 d after period end